novo nordisk compounded semaglutide Hims? Hers? It's Nordisk's Market Now Hims & Hers plans to

New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.

Triagonists (for example GLP-1/GIP/glucagon) are currently in pre-clinical or early clinical development

The metabolic correction is lifesaving.

Why Verification Matters in UAE

Everyone talks about the side effects of GLP-1 medications (Linkedin Experts) but very few people stop to put risk into proper perspective

Obesity is a topic guaranteed to generate discussion since the advent of Social Media, but the more recent launch of effective prescription medications to treat people who are overweight and live with obesity, on and off label, has all the characteristics of a Social Media phenomenon